Friday, July 10, 2026

pharma · Steroid refractory Acute Graft versus host Disease · moderate to severe atopic dermatitis

Medac Gesellschaft fuer

Medac Gesellschaft fuer is a pharma organization headquartered in EU. Primary therapeutic focus areas include Steroid refractory Acute Graft versus host Disease, moderate to severe atopic dermatitis. NovaPharmaNews links

EU HQ
EMA registrant Type
Company details
Status
Public
HQ
EU
Programs
3
Drugs
14
Patents
0
Clinical program

MC-FludT.18/QT

Phase 1 · other · Subjects with AML ( Acute myeloid leukaemia) or MDS (Myelodysplastic syndrome) undergoing allogeneic hematopoietic stem cell transplantation

MC-FludT.18/QT for Subjects with AML ( Acute myeloid leukaemia) or MDS (Myelodysplastic syndrome) undergoing allogeneic hematopoietic stem cell transplantation is a Phase 1 program (other) at Medac Gesellschaft fuer klinische Spezialpraeparate mbH with 1 ClinicalTrials.gov record(s).

Internal code MC-FludT.18/QT

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Medac Gesellschaft fuer klinische Spezialpraeparate mbH
Phase
Phase 1
Modality
other
Indication
Subjects with AML ( Acute myeloid leukaemia) or MDS (Myelodysplastic syndrome) undergoing allogeneic hematopoietic stem cell transplantation
Status
active
Trials
1